-
摘要:
目的 检测BRAFV600E突变在甲状腺乳头状癌(PTC)中的发生情况, 分析BRAFV600E突变与临床各病理参数以及与合并桥本氏甲状腺炎(HT)和结节性甲状腺肿的关系。 方法 天津医科大学附属肿瘤医院2011年3月至2011年8月所收治的临床考虑甲状腺癌患者112例, 术中取部分新鲜肿瘤组织, 送基因诊断室检测BRAFV600E突变情况, 其中30例患者同时取部分正常甲状腺组织进行检测对照。 结果 112例患者病理结果显示110例为PTC, 2例为结节性甲状腺肿。其中BRAFV600E突变在110例PTC的突变率为62.7%, 不存在于结节性甲状腺肿及正常甲状腺组织。年龄≤30岁PTC患者8例, 突变率为25.0%;30~60岁患者86例, 突变率为62.8%;≥60岁患者16例, 突变率为81.2%, 差异有统计学意义(P=0.027)。、BRAFV600E突变与其他临床病理参数间的差异无统计学意义。合并HT的PTC患者40例, 突变率42.5%;未合并HT的PTC患者70例, 突变率74.3%, 差异有统计学意义(P=0.001)。合并结节性甲状腺肿的PTC患者61例, 突变率72.1%;未合并结节性甲状腺肿的PTC患者49例, 突变率51.0%, 差异有统计学意义(P=0.023)。 结论 PTC的BRAFV600E突变率可能与种族差异有关。BRAFV600E突变率可能与患者年龄构成比有一定的相关性。合并HT的PTC BRAFV600E突变率低, 而合并结节性甲状腺肿的PTC BRAFV600E突变率高。 Abstract:Objective To detect BRAFV600E mutation in papillary thyroid carcinoma(PTC); to analyze the relationship between BRAFV600E mutation and clinicopathologic parameters in PTC; and to investigate BRAFV600E mutation in PTC coexisting with Hashimoto's thyroiditis or nodular goiter. Methods DNA was extracted from the fresh thyroid tumor tissues of 112 patients and from normal tissues of 30 patients who were treated in our institution from March 2011 to August 2011 and diagnosed with thyroid carcinoma before surgery.BRAFV600E mutation was detected via polymerase chain reaction and DNA sequencing assays.Clinical data were reviewed and evaluated using the SPSS17.0 statistical software package. Results The pathology showed that the 112 Chinese patients consisted of 110 cases of PTC and 2 cases of nodular goiter.The presence of BRAFV600E mutation was found in 69 patients with PTC(62.7%); the mutation was detected only in PTC and not in the 2 patients with nodular goiter as well as in the 30 normal tissues near the tumor.A significant difference in the BRAFV600E mutation rates in the≤30, 30-60, and≥60 age groups(25.0%, 62.8%, and 81.2%, respectively) was found.However, statistical data did not show any correlation between BRAFV600E mutation and other clinicopathologic parameters in PTC.The BRAFV600E mutation rate in PTC coexisting with Hashimoto's thyroiditis was 42.5%, whereas that in PTC coexisting with nodular goiter was 72.1%.These results both showed a significant difference with PTC not coexisting with benign thyroid lesion. Conclusion Differences in genetic backgrounds might explain the differences in the BRAFV600E mutation rates.The rate obtained in the study is higher than the results in western countries but lower than that in Korea.The BRAFV600E mutation rates are different in different age groups.The rate obtained in PTC coexisting with Hashimoto's thyroiditis is low, whereas a high rate was obtained in PTC coexisting with nodular goiter. -
Key words:
- Papillary thyroid carcinoma /
- Mutation /
- BRAF /
- Nodular goiter /
- Hashimoto's thyroiditis
-
表 1 BRAFV600E突变与PTC患者临床病理参数间的关系 例（%）
Table 1. Correlation between BRAFV600E mutation and clinicopathologic parameters in PTC
表 2 年龄对BRAFV600E突变的影响 例（%）
Table 2. BRAFV600E mutation in ≤30, 30~60, and≥60 age groups
表 3 合并桥本氏甲状腺炎与BRAFV600E突变的相关性 例（%）
Table 3. BRAFV600E mutation in PTC coexisting with Hashimoto's thyroiditis
表 4 合并结节性甲状腺肿与BRAFV600E突变的相关性 例（%）
Table 4. BRAFV600E mutation in PTC coexisting with nodulor goiter
-
[1] Kim SJ, Lee KE, Myong JP, et al. BRAFV600E mutation is associated with tumor aggressiveness in papillary thyroid cancer[J]. World J Surg, 2012, 36(2): 310-317. http://www.onacademic.com/detail/journal_1000034451817710_ff4a.html [2] Frasca F, Nucera C, Pellegriti G, et al. BRAFV600E mutation and the biology of papillary thyroid cancer[J]. Endocr Relat Cancer, 2008, 15(1): 191-205. http://www.researchgate.net/profile/Veronica_Vella/publication/5542688_BRAFV600E_mutation_and_the_biology_of_papillary_thyroid_cancer/links/5557508708aeaaff3bf76ed5/BRAFV600E-mutation-and-the-biology-of-papillary-thyroid-cancer.pdf [3] Kim KH, Kang DW, Kim SH, et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population[J]. Yonsei Med J, 2004, 45(5): 818-821. doi: 10.3349/ymj.2004.45.5.818 [4] Proietti A, Giannini R, Ugolmi C, et al. BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features[J]. Thyroid, 2010, 20(11): 1263-1270. http://www.researchgate.net/profile/Riccardo_Giannini/publication/47447525_BRAF_Status_of_Follicular_Variant_of_Papillary_Thyroid_Carcinoma_and_its_Relationship_to_Its_Clinical_and_Cytological_Features/links/0c960533e9a42a83a3000000/BRAF-Status-of-Follicular-Variant-of-Papillary-Thyroid-Carcinoma-and-its-Relationship-to-Its-Clinical-and-Cytological-Features.pdf [5] Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2005, 90(12): 6373-6379. http://www.ncbi.nlm.nih.gov/pubmed/16174717?dopt=AbstractPlus [6] Sassolas G, Hafdi—Nejjari Z, Ferraro A, et al. Oncogenic alterations in papillary thyroid cancers of young patients[J]. Thyroid, 2012, 22 (1): 17-26. http://smartsearch.nstl.gov.cn/paper_detail.html?id=fabc5f00231fc401f1f79f1e901e2d96 [7] Nikiforova MN, Ciampi R, Salvatore G, et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas[J]. Cancer Lett, 2004, 209(1): 1-6. http://www.researchgate.net/profile/Tetiana_Bogdanova/publication/8559678_Low_prevalence_of_BRAF_mutations_in_radiation-induced_thyroid_tumors_in_contrast_to_sporadic_papillary_carcinomas/links/00b7d51f23c9d6ecb7000000 [8] Lima J, Trovisco V, Soares P, et al. Reply to: Low prevalence of BRAF mutations in radiationinduced thyroid tumors in contrast to sporadic papillay carcinomas[J]. Cancer Lett, 2005, 230(1): 149-150. [9] Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto's thyroiditis and the role of PI3k/Akt pathway[J]. J Am Coll Surg, 2007, 204(5): 764-773. http://www.sciencedirect.com/science?_ob=ShoppingCartURL&_method=add&_eid=1-s2.0-S1072751507000026&originContentFamily=serial&_origin=article&_ts=1418643628&md5=1e3fadb88b55de93256635310672d847 [10] Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis[J]. Thyroid, 2009, 19(2): 137-141. http://europepmc.org/abstract/med/19014278 -
点击查看大图
表(4)
计量
- 文章访问数: 122
- HTML全文浏览量: 15
- PDF下载量: 4
- 被引次数: 0
下载:
